| Vice President Hyun-hee Na and Director Sung-kyung Lee Appointed… Participating in identifying promising pharma/bio technologies and collaborating on commercialization.
Hyun-hee Na (Vice President) and Sung-kyung Lee (Director) of JNPMEDI (CEO Kwon-ho Jung)—an AI platform-based consulting firm for drug and innovative medical device development—have been appointed as committee members for the 26th term of the Pharmaceutical Technology Transfer Center (PTTC) Technology Transfer Committee.
The appointment took place at the "26th PTTC Technology Transfer Committee Launch and Appointment Ceremony" held last month at the Samjung Hotel in Gangnam-gu, Seoul. The event was hosted by the Korea Drug Research Association (KDRA) and organized by the PTTC.
The 26th term of the Technology Transfer Committee consists of 155 experts from 94 companies and organizations in the pharmaceutical and bio-health sectors. At this launch ceremony, appointment letters were presented to 42 individuals from 30 companies, including JNPMEDI, who were either newly appointed or replaced.
From JNPMEDI, Vice President Hyun-hee Na of the Clinical Strategy Group and Director Sung-kyung Lee of the Science & Business Development (S&BD) Center were newly appointed as technology transfer committee members.
Leveraging JNPMEDI’s expertise in clinical strategy, business development, and regulatory affairs, the two executives will participate in the committee’s activities. They are expected to contribute to expanding industry cooperation by matching technology demands with promising innovations and reviewing possibilities for joint research and investment linkage.
Furthermore, they plan to participate in various technology transfer activities, such as technology briefing sessions, partnering programs, and global cooperation projects, to expand collaboration opportunities between companies and support activities that lead to technology commercialization.
Sung-kyung Lee, Director of JNPMEDI’s Science & Business Development Center, stated, "With this appointment, we will integrate JNPMEDI's science-based business development insights and clinical strategy expertise into the entire lifecycle of technology transfer and commercialization. We aim to be a 'Value-up' partner that maximizes the value of Korea's promising pipelines."
She further emphasized, "Beyond simple pipeline matching, we will serve as a strategic catalyst to ensure that innovative technologies in the pharma/bio industry achieve actual market success by providing integrated solutions that encompass clinical trials and regulatory response."
| Vice President Hyun-hee Na and Director Sung-kyung Lee Appointed… Participating in identifying promising pharma/bio technologies and collaborating on commercialization.
Hyun-hee Na (Vice President) and Sung-kyung Lee (Director) of JNPMEDI (CEO Kwon-ho Jung)—an AI platform-based consulting firm for drug and innovative medical device development—have been appointed as committee members for the 26th term of the Pharmaceutical Technology Transfer Center (PTTC) Technology Transfer Committee.
The appointment took place at the "26th PTTC Technology Transfer Committee Launch and Appointment Ceremony" held last month at the Samjung Hotel in Gangnam-gu, Seoul. The event was hosted by the Korea Drug Research Association (KDRA) and organized by the PTTC.
The 26th term of the Technology Transfer Committee consists of 155 experts from 94 companies and organizations in the pharmaceutical and bio-health sectors. At this launch ceremony, appointment letters were presented to 42 individuals from 30 companies, including JNPMEDI, who were either newly appointed or replaced.
From JNPMEDI, Vice President Hyun-hee Na of the Clinical Strategy Group and Director Sung-kyung Lee of the Science & Business Development (S&BD) Center were newly appointed as technology transfer committee members.
Leveraging JNPMEDI’s expertise in clinical strategy, business development, and regulatory affairs, the two executives will participate in the committee’s activities. They are expected to contribute to expanding industry cooperation by matching technology demands with promising innovations and reviewing possibilities for joint research and investment linkage.
Furthermore, they plan to participate in various technology transfer activities, such as technology briefing sessions, partnering programs, and global cooperation projects, to expand collaboration opportunities between companies and support activities that lead to technology commercialization.
Sung-kyung Lee, Director of JNPMEDI’s Science & Business Development Center, stated, "With this appointment, we will integrate JNPMEDI's science-based business development insights and clinical strategy expertise into the entire lifecycle of technology transfer and commercialization. We aim to be a 'Value-up' partner that maximizes the value of Korea's promising pipelines."
She further emphasized, "Beyond simple pipeline matching, we will serve as a strategic catalyst to ensure that innovative technologies in the pharma/bio industry achieve actual market success by providing integrated solutions that encompass clinical trials and regulatory response."